Fibromyalgia Treatment Trial Sparks Increase in Requests for EpicGenetics’ Diagnostic Test

Fibromyalgia Treatment Trial Sparks Increase in Requests for EpicGenetics’ Diagnostic Test
A 50 percent uptick in the past couple of months in applications for a diagnostic blood test called FM/a for fibromyalgia is largely due to a new clinical trial testing a tuberculosis vaccine for treating the condition, according to EpicGenetics, which developed the test. The collaborative Massachusetts General Hospital Phase 2 trial is investigating the use of a generic vaccine called BCG, globally used to prevent tubercolosis, to treat and reverse fibromyalgia. In September, the U.S. Food and Drug Administration approved the EpicGenetics-funded trial, which the company says has resulted in more requests for the FM/a test. "I regularly hear from patients who are thankful for a test that legitimizes their disease and saves them time and money of the traditional ‘rule out’ method,” Bruce Gillis, MD, EpicGenetics' CEO, said in a press release. "Patients are mobilizing because now, for the first time, there is hope. They have the chance of a treatment that does more than merely mask the symptoms. It actually addresses the disease of fibromyalgia.” The 2012 federal approval of FM/a, the first blood test for fibromyalgia, led California-based EpicGenetics to expand its re
Subscribe or to access all post and page content.